- Home
- ASRV vs KLRS Comparison
ASRV vs KLRS Comparison
Compare ASRV & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASRV | KLRS |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 92.8M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASRV | KLRS |
|---|---|---|
| Price | $4.74 | $2.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 11.6K | ★ 51.3K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | 61.90 | ★ 75.70 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $14,634,000.00 | $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.81 |
| 52 Week High | $5.38 | $11.88 |
Technical Indicators
Market Signals| Indicator | ASRV | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 25.01 |
| Support Level | $3.62 | N/A |
| Resistance Level | $5.09 | $4.37 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 42.19 | 7.26 |
Price Performance
Historical ComparisonAbout ASRV AmeriServ Financial Inc.
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.